BioMarin Pharmaceutical (BMRN): An Asymmetric Opportunity at $59
BioMarin is undervalued due to market pessimism. The acquisition of Amicus Therapeutics and the divestment of Roctavian are positive catalysts. The company has a strong portfolio of rare disease drugs and is targeting 40% operating margins. The price target is $86, representing a 45% upside.
Automatically collect high-quality investment opinions from across the web daily
Over 50+ high-quality investment ideas await you every day
Investment insights from 15+ platforms like Substack, Seeking Alpha, X/Twitter, with AI-powered summaries, categorized by industry. Register for free to access all features.